Literature DB >> 4087195

Kinetics of phosphoramide mustard hydrolysis in aqueous solution.

E Watson, P Dea, K K Chan.   

Abstract

Hydrolysis of phosphoramide mustard was investigated using HPLC, 31P NMR, and GC-MS with specific deuterium labels. The hydrolysis of phosphoramide mustard in sodium phosphate buffers was found to follow apparent first-order kinetics. The rate of hydrolysis was temperature and pH dependent, being slower under acidic conditions. The hydrolysis was not catalyzed by hydroxyl ion, and its pH dependence appeared to be the result of a change in the mechanism of hydrolysis at different pH values. At a pH value approximately above the pKa of the phosphoramide mustard nitrogen, the major hydrolytic pathway of phosphoramide mustard was via the formation of the aziridinium ion, followed by nucleophilic attack. At pH values below its pKa, cleavage of the P-N bond predominated. At pH 7.4, the formation of an aziridinium ion was followed by a rapid hydrolysis to yield the monohydroxy and, subsequently, the dihydroxy products. The hydrolysis at this pH was adequately described by consecutive first-order kinetics. Seven species in the hydrolytic mixture have been identified as intact phosphoramide mustard, N-(2-chloroethyl)-N-(2-hydroxyethyl)phosphorodiamidic acid, N,N-bis-(2-hydroxyethyl)phosphorodiamidic acid, phosphoramidic acid, phosphoric acid, N,N-bis-(2-chloroethyl)amine, and N-(2-chloroethyl)-N-(2-hydroxyethyl)amine by GC-MS with the aid of deuterium labels. Phosphoramide mustard was found to be stabilized by chloride ion. The stabilization was linearly related to the chloride ion concentration, and the mechanism was found to be via the formation of phosphoramide mustard from the aziridinium and chloride ions. Phosphoramide mustard was significantly more stable in human plasma and in 5% human serum albumin as compared to aqueous buffers, an observation that may be important in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087195     DOI: 10.1002/jps.2600741208

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

Authors:  C P Coyne; Lakshmi Narayanan
Journal:  J Pharm Drug Deliv Res       Date:  2015-03-20

3.  Kinetics of hydrolysis in vitro of nornitrogen mustard, a metabolite of phosphoramide mustard and cyclophosphamide.

Authors:  K Hemminki; A Alhonen; E Linkola; A Hesso
Journal:  Arch Toxicol       Date:  1987-12       Impact factor: 5.153

4.  Involvement of a volatile metabolite during phosphoramide mustard-induced ovotoxicity.

Authors:  Jill A Madden; Patricia B Hoyer; Patrick J Devine; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2014-03-15       Impact factor: 4.219

5.  Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Drug Des Devel Ther       Date:  2016-08-12       Impact factor: 4.162

6.  Hydrolytic stability of anticancer drugs and one metabolite in the aquatic environment.

Authors:  Michał Toński; Joanna Dołżonek; Piotr Stepnowski; Anna Białk-Bielińska
Journal:  Environ Sci Pollut Res Int       Date:  2021-06-08       Impact factor: 4.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.